Showing posts with label FUDR. Show all posts
Showing posts with label FUDR. Show all posts

Saturday, February 3, 2018

Back on the sauce

I mentioned in my last post, on January 8, 2018, that back on December 29, 2017 Sloan Kettering had finished tapering off my steroid treatment, and that I hadn’t been feeling so well since they did so. (I’d been receiving the steroids to deal with the inflammation of my liver that I’d experienced in late 2017, apparently a side-effect of the chemotherapy; meanwhile I was on chemotherapy “holiday.”) After that post I continued to not feel well: my energy was low, my digestion upset. Meanwhile I wasn’t receiving any treatment at all: the steroids had been tapered off to zero, and the oncologist felt that my December scan showed I was doing well enough that I should continue without chemotherapy unless my tumors resumed growing. It was, frankly, a bit weird to have no treatment going on, while something – I didn’t know what – was happening to my body. But I described all this to the Sloan Kettering folks (special hat tip to my oncologist’s nurse, with whom I spoke in detail), and they decided to schedule my next scan a little earlier than they otherwise might have.

So I got scanned on January 23. Each time I do an MRI I’m puzzled again about exactly what I’m supposed to do as the patient. Not long ago I was told that I was breathing too faintly, which seemed to be the result of my falling asleep during the scan; this time the MRI staff said it was fine if I went to sleep, but then they redid one part of the scan because I was breathing too heavily! I’m not sure what a good scan actually looks like – to my eyes they all seem pretty hard to decipher – but it does appear that whatever a good scan is, there are multiple ways of going about getting it. Some MRI staff favor one approach, some another. For sure, the human interaction between the patient and the MRI staff is important to the successful use of this high-tech tool.

But in any case I did well enough to produce clear images. We learned the next day, January 24, that what the images showed was renewed growth of my tumors, mostly but not always growth measurable in millimeters. And that in turn meant that our oncologist decided chemotherapy should resume – that very day. I’m back on the combination of FUDR and mitomycin, administered through separate channels of my intrahepatic pump. The FUDR dose has been reduced, to limit the chance that my liver will again get inflamed, but the oncologist is confident that a reduced dose can still be clinically effective. I’ll be on the current infusion till this coming Wednesday, February 7, then off for about two weeks, and then, assuming my liver has tolerated the resumption of chemo all right, the next round will start on Friday, February 23.

It would have been better news, of course, if my tumors were still stable or even contracting. But this news is at least clarifying: I wasn’t feeling well, and it’s plausible to think that the reason is that the tumors were growing. Tumor growth, it seems, takes its own toll on my body. The best news is that since I’ve gone back onto chemotherapy, I’ve definitely felt better. At first it seemed possible that this was because of the steroids which accompany the chemotherapy, since after the steroids were tapered off to zero at the end of 2017, I was actually on a steroid holiday as well as a chemotherapy holiday. But at this point the amount of steroid I’m getting via the pump is very small (something like a milliliter a day, and flowing into my liver rather than directly into the rest of my body), and so I suspect that the reason I’m feeling better is that the chemo itself is working and I really am better. Hopefully the next scan, probably a month or two from now, will confirm what I think my body is saying.


Whether it does or doesn’t, though, it’s clear that it’s time for us to think seriously about clinical trials or other treatments, since at some point the FUDR/mitomycin combination may lose its impact. Teresa and I have just been to the Cholangiocarcinoma Foundation’s excellent annual conference in Salt Lake City, where we learned a great deal about the current state of the science and the clinical trials that are getting underway. I wouldn’t say we got a lot of answers, but we certainly came home with many new questions – some of which I’m sure I’ll be writing about in future blog posts.

Saturday, August 26, 2017

My current chemo -- an update

I’ve now had two rounds of the new regime – an infusion of mitomycin over a 45-minute period, and a two-week infusion of FUDR, both injected through my pump. Now I’m in the two-week off period that follows each round of treatment, and soon I will have a scan that will say whether the new treatment is working.

Meanwhile, I’ve learned more about the treatment itself. First, I’m pretty sure now that I was wrong to write after the first set of infusions that a single needle seemed to have been used for two separate insertions, one for each of the two drugs being injected into the pump. In hindsight, that doesn’t really seem conceivable, and my impression from the second set of infusions was that in fact a new needle was used for each of the two drugs. I guess the sheer size of those needles distracts me. (They need to be long, by the way, because they’re not primarily going into me – instead they’re going through a little bit of me on the way to their target in the pump. But even the nurse for one of the rounds agreed that they are big needles.)

Second, yesterday for the first time I grasped how much of the FUDR is actually going to my liver in the two-week infusion process. The answer for the past two weeks was: 18 cubic centimeters. I know this because the nurse drained 12 cc’s  of the drug from the pump, and she explained that they expect to drain between 10 and 15 cc’s – out of a total of 30 cc’s that they put in at the start of the process. (Once the medicine is drained at the end of the two-week treatment period, by the way, the pump is then loaded for the two-week off period with an inert substance, a mixture of saline solution and heparin, an anti-clotting agent.) So that means that over the two weeks of the infusion, just a shade over 1 cc of FUDR was making its way to my liver each day. That must say something about how powerful a drug FUDR is. I hope that power is making itself felt against the tumors. It’s also probably having some impact on my healthy liver cells, but fortunately the blood test results show that my liver is doing well despite these medical affronts.  

Third, after the latest infusion I had two or three days of abdominal discomfort. It appears that this may have been, essentially, acid reflux, and fortunately the treatment Memorial Sloan Kettering prescribed – increasing my anti-acid reflux medications, including the old standby, Pepto-Bismol – seemed to address my symptoms. But what was most surprising about this was the comment of the MSK nurse, who told me that any use of the pump, even with inert substances, can cause difficulties like this. This I suppose is further proof that you can’t fool Mother Nature – if you put a foreign object inside your abdomen and inject things through it to your liver, your body may acquiesce but it won’t necessarily be pleased.


-->
Still, if the scan results are good, I’ll be happy to continue treating acid reflux!

Saturday, July 22, 2017

My new treatment

One purpose of this blog is just to describe how cancer treatment is done – at least how it’s done in my case – and since there’ve been new developments in my treatment it’s time for a new description.

I’m no longer receiving my chemotherapy through my port – the ingenious entry-way implanted just below my right collarbone that enabled me to stop having chemo through my increasingly stressed veins. Now I’m back receiving the chemotherapy through my intra-hepatic pump – the other ingenious device that’s been implanted in me. This one is a good deal larger, and required abdominal surgery last August to install; its function is to send chemo directly to the liver.

The pump was installed, almost a year ago, with the immediate goal of putting me in a clinical trial using one drug, FUDR, via the pump and another, gemcitabine, intravenously. Unfortunately I failed out of that trial when a new tumor appeared in January, and then I went onto intravenous treatment, or rather treatment via the port, with a different set of medications, called 5FU and irinotecan. The intravenous treatment has now failed too, or at least not succeeded; that’s the import of the presence of the two or three small, new, “atypical” tumors I wrote about last week. And now, as I said already, we’re back to the pump, but not quite the same way as last time.

The process started last Tuesday (July 11) with a steroid, meant to combat side effects; that did go in through the port, but that was the only use made of the port. Then I got two chemotherapy drugs. One was FUDR, which was part of the clinical trial combination too. I’m not quite sure why we’ve returned to this drug, but I take it that the doctors think that, at least in combination with the other one I’m now getting, it can still be effective even though it didn’t succeed back in January. Anyway, FUDR went into the pump first, into a compartment of the pump from which it infuses into my liver over a two-week period, which is still ongoing. Then the nurse took the needle out – the rather big needle that penetrates the skin of my abdomen and then goes into the pump. But that wasn't the end.

Next the nurse connected up a container of a second drug, called mitomycin; this is the new drug (new for me, that is) that’s been added to the mix.  Then she – my nurse was a woman – put the needle back into my abdomen, in what seemed to me to be the exact same spot she’d used the first time! I think it was the same needle, but I admit I might be wrong about that; maybe it was another needle, equally large. It looked to me as if the needle had wound up going in in the very spot where a drop of blood had emerged from the first injection; but, again, I might be wrong, and maybe that drop of blood (only one) was new. I was a bit rattled! Anyway, even though the needle had gone in in essentially the same spot both times, the second time the nurse, in some way that I didn’t quite follow, used the needle to access a different compartment of the pump, one that doesn’t store the drug but sends it immediately to the liver. And then this drug was administered via this hook-up over a 45-minute period, during which I was told I needed to stay very still, which I did my best to do.


The alarmingly large needle hurt for a moment as it was inserted each time, but only for a moment. So the experience of having two injections into the pump during the same few minutes was actually only strange, not really painful. The whole process did require me to take a long look at my tummy, though, and since I’ve gained weight while being treated for cancer – a good thing – the esthetics to my mind left a good deal to be desired.